NEW YORK (360Dx) – Proteomics startup Seer Biosciences is developing a nanotechnology-based platform that it says will enable rapid, deep, and inexpensive proteome-scale analyses.

The South San Francisco, California-based company is focused on early detection of diseases in oncology and neurology and plans to launch its first product as a laboratory-developed test in 2021, said Omid Farokhzad, Seer's founder and CEO.

To support these efforts, the company has raised $36 million in funding through Series A and B rounds led by Maverick Ventures and Invus, respectively.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.